The malaria parasite may be gaining resistance against artemisinin, the drug most often used to try and save children with ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

Scientists have detected resistance to artemisinin, a key malaria drug, for the first time among children in Africa with ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...